España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Vericel
VCEL
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$46.68
1.77
3.94%
At Close: -
$46.68
0
0.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Get Report
Watch
Vericel (VCEL) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Vericel (NASDAQ:VCEL) Stock
Vericel Stock (NASDAQ: VCEL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, June 20, 2024
Vericel shares are trading higher after TD Co...
Benzinga Newsdesk
TD Cowen Initiates Coverage On Vericel with B...
Benzinga Newsdesk
Thursday, May 09, 2024
Critical Insights From Vericel Analyst Ratings: What You Need To Know
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Vericel,...
Benzinga Newsdesk
Wednesday, May 08, 2024
Vericel Raises FY24 Revenue Guidance From $23...
Benzinga Newsdesk
Vericel Q1 EPS $(0.08) Beats $(0.11) Estimate...
Benzinga Newsdesk
Tuesday, March 26, 2024
Analyst Scoreboard: 5 Ratings For Vericel
Benzinga Insights
Truist Securities Reiterates Buy on Vericel, ...
Benzinga Newsdesk
Friday, March 01, 2024
A Closer Look at 4 Analyst Recommendations For Vericel
Benzinga Insights
Truist Securities Maintains Buy on Vericel, R...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Vericel,...
Benzinga Newsdesk
Thursday, February 29, 2024
Vericel Forecasts 2024 Revenue Of $237M-$241M...
Benzinga Newsdesk
Vericel Q4 GAAP EPS $0.26 Beats $0.17 Estimat...
Benzinga Newsdesk
Earnings Scheduled For February 29, 2024
Benzinga Insights
Thursday, January 25, 2024
Truist Securities Upgrades Vericel to Buy, Ra...
Benzinga Newsdesk
Tuesday, January 16, 2024
HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Vericel,...
Benzinga Newsdesk
Tuesday, January 09, 2024
Vericel shares are trading higher after the c...
Benzinga Newsdesk
Vericel FY23 Prelim. Total Net Revenue Expect...
Benzinga Newsdesk
Thursday, December 28, 2023
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Shivani Kumaresan
Thursday, November 09, 2023
Truist Securities Maintains Hold on Vericel, ...
Benzinga Newsdesk
Truist Securities Maintains Hold on Vericel, ...
Benzinga Newsdesk
Wednesday, November 08, 2023
Vericel Raises 2023 Revenue Guidance From $19...
Benzinga Newsdesk
Vericel Q3 EPS $(0.08) Vs $(0.14) Last Year, ...
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights
Monday, October 16, 2023
Analyst Ratings for Vericel
Benzinga Insights
Leerink Partners Initiates Coverage On Verice...
Benzinga Newsdesk
Thursday, September 28, 2023
Vericel Announces Publication Of Results From...
Benzinga Newsdesk
Thursday, September 21, 2023
Truist Securities Reiterates Hold on Vericel,...
Benzinga Newsdesk
Stephens & Co. Reiterates Overweight on Veric...
Benzinga Newsdesk
Analyst Ratings for Vericel
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Vericel,...
Benzinga Newsdesk
Wednesday, September 20, 2023
Vericel Announces U.S. Commercial Availability Of NexoBrid For The Treatment Of Severe Thermal Burns In Adults
Happy Mohamed
Vericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of Losses
Vandana Singh
Watching Vericel Corp.; J Capital Research Is...
Benzinga Newsdesk
Tuesday, August 29, 2023
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Faith Ashmore
-
Sponsored
Tuesday, August 08, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Benzinga Insights
BTIG Upgrades Vericel to Buy, Announces $39 P...
Benzinga Newsdesk
Thursday, August 03, 2023
Expert Ratings for Vericel
Benzinga Insights
Truist Securities Maintains Hold on Vericel, ...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Vericel,...
Benzinga Newsdesk
Wednesday, August 02, 2023
Earnings Scheduled For August 2, 2023
Benzinga Insights
MediWound Said Partner Vericel Has Received The First Lot Of Nexobrid Finished Product From Mediwound For The U.S. Commercial Market In June 2023
Charles Gross
Vericel Revises FY23 Revenue Guidence To $190M-$197M From $184M-$192M Vs $190.29M Est.
Happy Mohamed
Vericel Q2 EPS $(0.11) Beats $(0.13) Estimate, Sales $45.92M Beat $42.81M Estimate
Happy Mohamed
Wednesday, July 19, 2023
Truist Securities Maintains Hold on Vericel, ...
Benzinga Newsdesk
Thursday, May 11, 2023
Truist Securities Maintains Hold on Vericel, ...
Benzinga Newsdesk
Stephens & Co. Maintains Overweight on Verice...
Benzinga Newsdesk
Wednesday, May 10, 2023
Earnings Scheduled For May 10, 2023
Benzinga Insights
Vericel: Q1 Earnings Insights
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch